Alnylam Pharmaceuticals

The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Company’s pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.
Company Growth (employees)
Cambridge, US
Size (employees)
514 (est)+40%
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, US

Key People at Alnylam Pharmaceuticals

Saraswathy (Sara) Nochur

Saraswathy (Sara) Nochur

Senior Vice President, Regulatory Affairs & Quality Assurance
Muthiah (Mano) Manoharan

Muthiah (Mano) Manoharan

Senior Vice President, Drug Discovery
Lubomir (Lubo) Nechev

Lubomir (Lubo) Nechev

Vice President, Process Sciences
Mary Beth DeLena

Mary Beth DeLena

VP, Legal
David Bartel

David Bartel

Scientific Advisory Board and Founder

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge and Uxbridge
Cambridge, US (HQ)
300 Third St
Cambridge, US
665 Concord Ave
Uxbridge, GB
Highbridge Industrial Estate Oxford Rd

Alnylam Pharmaceuticals Metrics

Alnylam Pharmaceuticals Financial Metrics

Net income (FY, 2015)

($290.1 m)

EBIT (FY, 2015)

($296 m)

Market capitalization (19-May-2017)

$6.2 b

Closing share price (19-May-2017)


Cash (31-Dec-2016)

$193.6 m
Alnylam Pharmaceuticals's current market capitalization is $6.2 b.
FY, 2013FY, 2014FY, 2015

Operating expense total

$140.1 m$455.5 m$337.1 m


($92.9 m)($405 m)($296 m)

Net Income

($89.2 m)($360.4 m)($290.1 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$53.2 m$75.2 m$180.9 m$193.6 m

Accounts Receivable


$3.9 m$9.7 m$16.6 m$21.7 m

Current Assets

$254 m$746.4 m$1.1 b$671.9 m


$16.4 m$21.7 m$27.8 m$114.6 m

Total Assets

$420.5 m$1.1 b$1.4 b$1.3 b

Accounts Payable

$5.9 m$15.1 m$16.8 m$54.5 m

Current Liabilities

$53.9 m$95.3 m$62.1 m$131.7 m

Additional Paid-in Capital

$846.2 m$1.8 b$2.5 b$2.6 b

Retained Earnings

($596.2 m)($956.6 m)($1.2 b)($1.7 b)

Total Equity

$270.3 m$936.3 m$1.3 b$920.2 m

Financial Leverage

1.6 x1.2 x1.1 x1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($89.2 m)($360.4 m)($290.1 m)($410.1 m)

Depreciation and Amortization

$10.2 m$11.9 m$19.1 m$15.1 m

Accounts Receivable


Accounts Payable

$1.8 m$8.8 m$1.7 m$10.1 m

Cash From Operating Activities

($68.7 m)($165.6 m)($189.1 m)($307.7 m)

Purchases of PP&E

($4 m)($9 m)($13 m)($64.6 m)

Cash From Investing Activities

($130.5 m)($548.8 m)($321.3 m)$142.6 m

Cash From Financing Activities

$200.9 m$736.5 m$616.2 m$177.8 m

Interest Paid

$1.1 m
Y, 2016

Financial Leverage

1.4 x

Alnylam Pharmaceuticals Market Value History

Alnylam Pharmaceuticals Median Salaries

Source: 19 public H-1B filings from Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Online Presence

Alnylam Pharmaceuticals News

Alnylam Pharmaceuticals Company Life

You may also be interested in